Global Cancer Immunotherapies Market 2016-2020 - Increase in Demand for Cancer Monoclonal Antibodies - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Cancer Immunotherapies Market 2016-2020" report to their offering.

The global cancer immunotherapies market is expected to grow at a CAGR of 15.17% during the period 2016-2020.

The emergence of targeted and combination therapies are being developed to treat all types of cancer. Targeted therapies, which exploit the surface markers or properties of diseased or infected cells, cause fewer adverse effects than conventional non-targeted therapies. For example, in 20% of the cases, breast cancer is associated with the overexpression of HER2. In such circumstances, drugs such as Herceptin and Kadcyla, which target HER2 receptors, are administered as monotherapies or in combination. Targeting multiple pathways reduces the risk of developing treatment-resistant disorders. Thus, combination therapies, which target distinct mechanisms, are highly efficacious in treating cancer.

According to the report, an increase in the demand for cancer monoclonal antibodies will have a big impact on the market. The development and rising demand for cancer monoclonal antibodies have been attributed to the recent understanding of the type of cancer at the molecular level. Monoclonal antibodies have a high affinity for specific disease cells and areas that need treatment. The use of cancer monoclonal antibodies is growing, including therapies such as radioimmunotherapy and antibody-directed enzyme prodrug therapy (ADEPT). The rising use of these antibodies in drug development increases the revenue generation in the global cancer monoclonal antibodies market, thereby contributing to market growth.

Further, the report states that the expiry of drug patents will lead to reduced sales of key drugs.

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Overview of cancer immunotherapies

PART 06: Pipeline portfolio

PART 07: Market landscape

PART 08: Market segmentation by type

PART 09: Geographical segmentation

PART 10: Market drivers

PART 11: Impact of drivers

PART 12: Market challenges

PART 13: Impact of drivers and challenges

PART 14: Market trends

PART 15: Vendor landscape

Companies Mentioned:

  • Amgen Inc.
  • Bristol-Myers Squibb
  • F. Hoffman-La Roche
  • GlaxoSmithKline Plc
  • Merck Inc.
  • Takeda Pharmaceuticals
  • AbbVie
  • ADC Therapeutics
  • Agensys
  • Astellas
  • AstraZeneca
  • Bayer
  • Biogen
  • Biotech Pharmaceutical
  • Boehringer-Ingelheim
  • Celgene
  • Celldex Therapeutics
  • Chugai Pharmaceutical
  • CTI BioPharma
  • Daiichi Sankyo
  • Eli Lilly
  • Fortress Biotech
  • Genmab
  • Immunomedics
  • (10+ Others)

For more information visit http://www.researchandmarkets.com/research/8gwng6/global_cancer

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716